Spotlight
Topics
DI Executive
Subscribe
- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New Centiloid Scoring and Tau PET Quantification Tools
Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.
The Food and Drug Administration (FDA) has granted 510(k) clearance of Centiloid scoring and tau positron emission tomography (PET) quantification, features that are available with the syngo.PET Cortical Analysis software (Siemens Healthineers).
Employing a 100-point scale for the assessment of beta-amyloid plaque, the Centiloid scoring feature can be utilized with three different beta-amyloid PET radiopharmaceuticals approved to detect Alzheimer’s disease, according to Siemens Healthineers.
Here is an example of tau-PET imaging. Tau PET quantification and Centiloid scoring, two new features with the syngo.PET Cortical Analysis software, were recently cleared by the Food and Drug Administration (FDA). (Images courtesy of Alzheimer’s & Dementia.)
The company said using the tau PET quantification feature in combination with the radiopharmaceutical flortaucipir (Tauvid. Eli Lilly) enables quantification of the distribution and density of tau protein tangles on brain PET scans.
“The ability to quantify the buildup of amyloid plaque and tau protein in the brains of Alzheimer’s disease patients can provide clinicians with important diagnostic and staging information pertaining to the disease,” said Martin Cordell, Ph.D., the director of product lifecycle management at Siemens Healthineers Molecular Imaging.“The addition of Centiloid scoring and tau PET quantification features to our syngo.PET Cortical Analysis software fortifies our integrated and comprehensive portfolio for detection, diagnosis, monitoring, and follow-up related to Alzheimer’s disease.”
Recent Videos
Related Content
Radiology ‘Game-Changer’: FDA Approves PET Agent for Enhanced Detection of Coronary Artery Disease
September 28th 2024Article
Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Article
Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
